Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2025 09:00 ET | Source: Incendia Therapeutics, Inc.

Incendia Therapeutics Presents Two Posters on its Lead Asset PRTH-101 in Thymic Cancers at the 15th International Thymic Malignancy Interest Group (ITMIG) Annual Meeting

Initial Phase 1 data suggest PRTH-101 contributes to disease control in recurrent/metastatic thymic epithelial carcinoma (TEC) with median progression-free survival (mPFS) of 7.9 months and 1 partial...